Loader
We have noticed an unusual activity from your IP 199.16.157.180 and blocked access to this
We have noticed an unusual activity from your IP 199.16.157.180 and blocked access to this
Tivumecirnon plus pembrolizumab elicited responses in recurrent or metastatic head and neck squamous cell carcinoma after checkpoint inhibitor exposure.
Vikram Narayan, MD, details the mechanism of action of the nadofaragene firadenovec and how the agent is impacting care for patients with BCG-unresponsive non–muscle invasive…
Raj Singh, MD, discusses the use of stereotactic body radiation therapy and stereotactic radiosurgery in the treatment of patients with lung cancer.
Learn more about what Crucial Catch is and how the NFL and ACS have teamed up to fight cancer. Find links to buy Crucial Catch…
OBX-115 was well tolerated and produced durable antitumor responses in patients with immune checkpoint inhibitor (ICI)-resistant advanced melanoma.
Although FAK inhibition alone has displayed modest activity to date, there is interest in developing FAK-targeted therapies for combination regimens.
Dr. Bose discusses his initial impressions of the case and how it compares to typical myelofibrosis cases seen in his practice.
Nature Reviews Cancer – Using the tumour microenvironment to improve therapy efficacy
This is “WICS: Physician Burnout, Mindfulness, and Resilience” by Society of Surgical Oncology on Vimeo, the home for high quality videos and the people…
Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the significance of the FDA approval of cilta-cel in relapsed/refractory multiple myeloma.